Clinical Trial Update: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase III trial comparing HD201 to Herceptin (trastuzumab) in HER2-positive early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HD201 (trastuzumab biosimilar)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Prestige Biopharma Limited | Conditions: HER2 Positive Breast Cancer | Phase 3 | Status: COMPLETED